Emyria Ltd (ASX:EMD)'s Michael Winlo discusses with Proactive promising results from a previously published study assessing the effects of MDMA (ecstasy) and a unique MDMA-analogue (UWA-101) in a Parkinson’s disease (PD) model. He says the results indicate that both MDMA and UWA-101 extend the duration of action of L-DOPA, a common treatment for PD, and reduce the proportion of time associated with L-DOPA induced dyskinesia (LID).
Emyria talks potential for new MDMA-analogues in treatment of Parkinson’s disease
